Introduction
A report of Kaposi sarcoma in young gay men in New York and San Francisco in 1981 was one of the first harbingers of AIDS [1] . Kaposi sarcoma was first described in 1872 by Moritz Kaposi as a relatively indolent angioproliferative tumor in elderly men [2] . Several epidemiological subtypes of Kaposi sarcoma were subsequently differentiated: classic Kaposi sarcoma (in Mediterranean and Eastern European regions); more aggressive endemic Kaposi sarcoma (in Africa); and transplantation-associated Kaposi sarcoma [3, 4] . Prior to the AIDS epidemic, Kaposi sarcoma was rare in the United States. The AIDS epidemic changed that [1, 5] .
Before development of effective antiretroviral therapy (ART), this new form, called AIDS-associated or epidemic Kaposi sarcoma, developed in up to 30% of AIDS patients [6, 7] . Unlike classic Kaposi sarcoma, AIDS-associated Kaposi sarcoma was often disseminated, rapidly progressive, and frequently fatal.
AIDS-associated Kaposi sarcoma was noted to develop in MSM, but less often in other HIV risk groups, suggesting a second infectious cause [8] . In 1994, using representational difference analysis, Chang and Moore identified a novel g-herpesvirus in an AIDS-associated Kaposi sarcoma tumor [9] . This virus, most closely related to Epstein-Barr virus, was called Kaposi sarcoma-associated
Epidemiology and transmission of Kaposi sarcoma-associated herpesvirus
Unlike most other herpesviruses, KSHV prevalence varies widely among different populations [4] (Table 2) . In general, KSHV is highly prevalent in Sub-Saharan Africa, is of intermediate prevalence in the Mediterranean and parts of Latin and South America, and is of low prevalence in the general population in Northern Europe, North America, and most of Asia. However, there are substantial differences in seroprevalence within these regions. Also, the prevalence in MSM is much higher in many areas, and is approximately 14-26% in the United States among HIV-uninfected men, and even higher (up to 58%) in HIV-infected MSM [19] . Four major subtypes (A-D) have been defined based on variability of the open reading frame (ORF) K1 gene. Geographic distribution of these subtypes suggest that KSHV is an ancient virus [20] . Interestingly, extremely high seroprevalence has noted among some relatively isolated populations, including certain Amerindian groups in the Amazon as well as in ethnic groups in Xinjang, China (Table 2) . Immunosuppression is an important cofactor for the development of Kaposi sarcoma and other KSHV-related diseases. Before the use of ART, 50% or more of HIV-infected patients with detectable KSHV were found to develop Kaposi sarcoma [11] . By contrast, Kaposi sarcoma develops in relatively infrequently in KSHV-infected patients without immunodeficiency [21, 22] .
KSHV transmission varies in different populations. KSHV may be secreted in saliva, and this is believed to be a principal means of spread [19] . KSHV viral load is substantially lower in semen, and this is not believed to be an important means of transmission [23] . An important portal of entry is the mouth; in sub-Saharan Africa, infection often occurs during childhood and is believed to be mediated by close contact and perhaps specific practices, such as food premastication [24, 25] . KSHV can be detected in the circulating B cells of otherwise healthy infected individuals [26] and may rarely be spread by blood transfusion in sub-Saharan Africa [27] . However, even in areas with high seroprevalence, the risk of spread by transfusion is less than 3% [28] . Transfusion practices used in the United States, such as the washing of red blood cells, substantially reduce this risk. KSHV may also be spread through solid organ transplantation [29] , which can be associated with KSHVassociated malignancies posttransplant in the setting of immunosuppression. In MSM, there continues to be a high rate of KSHV transmission even when safer sex practices are utilized [19, 30] . Important routes of spread among MSM are believed to be the use of saliva as a lubricant during anal sex, oral-anal sex, and deep oral kissing [30, 31] . The mouth has a number of antiviral defenses which are lacking in the anus; thus, small tears in anal tissue may be a particularly vulnerable entry point.
KSHV is a necessary cause of KSHV-associated malignancies. If spread could be halted, this would prevent the subsequent development of KSHV-associated tumors. Unlike other herpesviruses, transmission of KSHV is relatively inefficient, and it should theoretically be feasible to develop an effective vaccine. However, to date there has been little economic incentive for this. Even without a vaccine, it may be possible to reduce the spread of KSHV through public health measures. There is currently almost no knowledge about KSHV among MSM, and advice to not use saliva as a lubricant in anal sex is a potential behavioral intervention to reduce transmission in this population. Also, increased education about other routes of KSHV transmission may help lead to a decrease in new infections. Additional research on these issues is needed to inform future public health policy.
Kaposi sarcoma-associated herpesvirus biology and disease pathogenesis KSHV is a large double-stranded DNA virus [32, 33] . It can infect several cell types, including B cells, monocytes, and endothelial cells. Like other herpesviruses, KSHV has latent and lytic replication programs. During latency, few genes are expressed, including those encoded by ORFK12 (kaposin); ORF71, viral FLICE-inhibitory protein (vFLIP); ORF72, (v-cyclin); ORF73 [latencyassociated nuclear antigen (LANA)]; ORFK10.5 (viral interferon response factors 3); and several viral microRNAs (miRNAs) [32, 33] . Lytic replication involves expression of all genes, production and release of progeny virions, and death of infected cells. The switch to lytic replication is mediated by replication and transcription activator (RTA), encoded by ORF50 [34] . A variety of physiologic signals can activate RTA, including hypoxia [35] , oxidative stress [36] , certain cytokines [37] , as well as certain chemicals, such as sodium butyrate and 12-Otetradecanoylphorbol-13-acetate (TPA).
KSHV encodes genes that can thwart innate cellular defenses, such as apoptosis or cell cycle arrest; subvert immunologic antiviral defenses; and promote proliferation of infected cells [32, 33] . Some KSHV genes mimichuman genes with angiogenic and inflammatory properties [38, 39] . Although the evolutionary pressure for these genes is to promote KSHV survival, they can also lead to the development of KSHV-related tumors and proliferative diseases, which are unintended consequences.
A few KSHV-encoded genes warrant specific mention. A viral interleukin-6 (vIL-6) induces the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway leading to increased expression of vascular epithelial growth factor (VEGF) and angiogenesis [40, 41] . vIL-6 also promotes cell proliferation and contributes to the symptomatology of KSHV-MCD [42] . LANA inhibits p53, decreasing apoptosis of KSHVinfected cells [43] . KSHV-encoded viral interferon response factors promote immune evasion by downregulation of major histocompatibility complex (MHC) proteins [44, 45] . In addition, KSHV-encoded K3 and K5
Kaposi sarcoma-associated herpesvirus diseases Gonçalves et al. 1905 Table 2 . Geographical estimates of Kaposi sarcoma-associated herpesvirus seroprevalence.
Geographic region KSHV seroprevalence
HIV uninfected general population Africa Uganda [156] 69%(mothers) 15% (children) Cameroon [157] 82% Nigeria [158] 24% (adults) Tanzania [158] 45% (adults) South Africa [64] 11% Europe and Mediterranean England [159] <5% blood donors Sicily, Italy [160] 9% general Central Italy [161] 20% Spain [162] 4% Israel [163] 10% Asia Japan [164] 5% Korea [162] 5% Thailand [162] 8-10% China [165, 166] Varies widely in different regions, from <6% to >18% in Xinjiang region Americas Argentina [162] 6% Brazilian Amazon [167] 65% (ages 0-9) and 92% in Mapuera Indians 10% (ages 0-9) and 50% (>35 years) in non-Mapuera Indians Colombia [162] 13% Costa Rica [162] 10% United States [168] 4% HIV infected
Cameroon [157] 84% HIV Johannesburg, South Africa [169] 48% United States [170, 171] 38-58% Peru [172] 67% Australia [173] 52% MSM (not HIV infected)
Shanghai China [174] 23% Japan [164] 12% Peru [172] 27% United States [170, 175] 14-26%% Sicily [176] 16% Eastern China [177] 3% Australia [173] 11%
ubiquinate surface MHC-1 and further contribute to downregulation, making infected cells invisible to effector T cells [46, 47] . Several KSHV encoded proteins upregulate human interleukin-6, including v-FLIP, kaposin B, and the product of ORF4 [48] . KSHV v-FLIP activates nuclear factor kappa-light-chain-enhancer of activated B cells [49] which contributes to the pathogenesis of PEL, Kaposi sarcoma, and KSHV-MCD [49] [50] [51] .
KSHV is somewhat unusual among oncogenic viruses in that several lytic genes play an important role in tumor pathogenesis. In Kaposi sarcoma and PEL, only a small percentage of infected cells express lytic genes [52, 53] . Even so, these genes are quite important in disease pathogenesis. In particular, there is evidence that a viral G-protein-coupled receptor, encoded by ORF74, plays a key role in Kaposi sarcoma [54] [55] [56] . In KSHV-MCD, KSHV-infected plasmablasts are the key cells driving the disease process. Many of these plasmablasts express vIL-6, and a substantial subset also express other lytic genes [53, [57] [58] [59] . It is unclear why different diseases develop in different KSHV-infected patients. One possibility is that differences in KSHV-encoded miRNA may contribute to different disease manifestations [60] .
Kaposi sarcoma
During the early AIDS epidemic, a substantial percentage of AIDS patients developed Kaposi sarcoma and it was an important cause of morbidity and mortality [61] . Soon after the introduction of the first antiretroviral drugs, its incidence decreased, and it fell further after the development of combination ART (cART) [62] . Even so, it remains the second commonest tumor in HIV patients, with approximately 900 cases per year in the US in recent years, including cases in patients on long term cART [63] . Furthermore, KSHV prevalence is high in sub-Saharan Africa [64, 65] , and both HIV-unrelated and HIV-associated Kaposi sarcoma are common in these regions. In some countries in sub-Saharan Africa, Kaposi sarcoma is the most common tumor in men [66] . Multiple factors will contribute to future epidemiologic trends, but given that aging is a risk for classic Kaposi sarcoma, it is possible that Kaposi sarcoma will become more common as the HIV-infected population ages.
Pathophysiology
Kaposi sarcoma is a multicentric hyperproliferative disease that most often presents with violaceous skin lesions. Microscopically, lesions consist of spindle-shaped tumor cells, often accompanied by fibrosis, inflammatory infiltrates, vascular slits, and hemosiderin. Immunohistochemical staining for CD31 is positive, and staining of spindle cells for KSHV LANA is sensitive and specific [12, [67] [68] [69] [70] [71] [72] (Fig. 1 ). Extravasated red blood cells give lesions a purplish hue. There is evidence that early in the course of Kaposi sarcoma, tumors are multiclonal [73, 74] . However, more advanced disease has been reported to be oligoclonal or monoclonal [73, 75] , and the clonality of Kaposi sarcoma is still an area of uncertainty.
The cell of origin of Kaposi sarcoma is a KSHV-infected vascular or lymphatic endothelial cell [76, 77] . Several KSHV genes are implicated in Kaposi sarcoma pathogenesis. As noted above, expression of KSHV vGPCR, a lytic protein, in a small subset of cells appears to play a key role [55, 56] . This constitutively active receptor leads to production of factors such as vascular epithelial growth factor, interleukin-6, interleukin-8, and tumor necrosis factor-a, which in turn promote Kaposi sarcoma through autocrine and paracrine activities. Cutaneous Kaposi sarcoma appears most frequently in the feet, which have poor oxygenation, especially in elderly men who develop classic Kaposi sarcoma. Hypoxia can induce RTA and other KSHV lytic genes, which may explain this association [35, 78, 79] . Interestingly, KSHV in turn enhances cellular levels of hypoxia inducible factors which mediate the cellular response to hypoxia, and this seems to be important in KSHV biology [80, 81] .
Kaposi sarcoma evaluation, staging, and treatment Apart from skin, Kaposi sarcoma can also develop in other locations, including oral mucosa, gastrointestinal tract, lymph nodes, and lung [82] . Skin lesions range from small patches to nodules. Diagnosis is made by biopsy. Pulmonary Kaposi sarcoma may be detected on chest X-ray or computerized tomography (Fig. 2) . In a patient with established Kaposi sarcoma, pulmonary disease is usually established by bronchoscopy with visualization of typical lesions and exclusion of other infectious etiologies. Biopsy of endobronchial lesion is generally avoided due to a risk of bleeding. Kaposi sarcoma may present anywhere along the gastrointestinal track. Although bulky disease may be symptomatic, gastrointestinal disease is often first detected through evaluation of occult blood loss and/or microcytic anemia. Workup with upper endoscopy and colonoscopy should be reserved for patients with symptoms or fecal blood loss.
Because Kaposi sarcoma is a multicentric disease, neither standard sarcoma staging nor the term metastases are useful. Patients are assessed on the extent of tumor, the status of the immune system, and the presence of systemic illness; for each parameter, a subscript of 0 is used to connote good risk and a subscript 1 poor risk [83] . For tumor burden, patients with tumor-associated edema or ulceration, extensive oral Kaposi sarcoma, gastrointestinal Kaposi sarcoma, or Kaposi sarcoma in other nonnodal viscera are considered poor risk (T 1 ), whereas patients with disease confined to the skin, lymph nodes, and nonnodular oral disease confined to the palate are considered good risk (T 0 ). (Table 3 ). The original staging criteria developed before availability of cART defined I 1 as a CD4 þ T-cell count less than 200 cells/ml. With cART, a CD4 þ T-cell counts of less than 100 or less than 150 cells/ml appear to be better prognostic thresholds [84] [85] [86] . Some investigators advocate eliminating immune system in Kaposi sarcoma staging, thus stratifying patients as poor risk (T 1 S 1 ) or good risk (T 1 S 0 , T 0 S 1 , or T 0 S 0 ). Pulmonary Kaposi sarcoma is associated with a particularly high risk of death [86] . In clinical studies, response to therapy is usually evaluated by Kaposi sarcoma-specific criteria [83] .
Patients with AIDS-related Kaposi sarcoma should be administered cART. Up to 80% of patients may have regression with cART alone; remissions are most likely in patients who are ART naïve, have limited disease, and achieve optimal HIV control [85, 87] . The median time to response varies from about 3 to 9 months. Substantial responses to cART are rare in patients with poor prognosis (T 1 S 1 ) disease [85, 88] . Some HIV-infected patients who are started on cART will develop Kaposi sarcoma or have an exacerbation of their existing Kaposi sarcoma that may be a manifestation of immune reconstitution inflammatory syndrome [89, 90] . There are no controlled trials to assess the optimal care of such patients, although systemic therapy for Kaposi sarcoma seems appropriate. Although steroids are utilized in patients with other manifestations of immune reconstitution inflammatory syndrome, they can substantially exacerbate Kaposi sarcoma [91] and should be avoided when possible.
In-vitro studies have shown that certain HIV protease inhibitors may have activity against Kaposi sarcoma, through antiangiogenesis activity or other mechanisms, and nelfinavir has been reported to inhibit KSHV replication [92, 93] . Several early clinical studies failed to find any advantage of protease inhibitor-containing cART regimens in preventing or treating Kaposi sarcoma [94, 95] . However, a more recent study that controlled for time on a given cART regimen found a reduction of Kaposi sarcoma in HIV-infected patients receiving boosted protease inhibitors (but not nelfinavir) after 2 years of treatment [96] , and this an area for future study.
Patients with a few small but problematic lesions can be treated with local therapy (topical 9-cis-retinoic acid, cryotherapy, radiation therapy, intralesional injections, or surgical resection), but results are often unsatisfactory and these approaches are now rarely used [16, 97, 98] . There are no hard criteria for systemic Kaposi sarcoma therapy, and the decision should be individualized. Systemic Kaposi sarcoma therapy is usually administered to patients with widespread T 1 disease, extensive cutaneous Kaposi sarcoma, symptomatic or life-threatening visceral Kaposi sarcoma, ulcerating Kaposi sarcoma, Kaposi sarcoma associated with edema, or tumor-related pain. Also, systemic therapy is justified in patients that fail to respond to cART, those with social withdrawal from Kaposi sarcoma, or when a rapid response is desired. For patients hospitalized with symptomatic Kaposi sarcoma, urgent therapy is often indicated, and may even need to be started in the intensive care unit. The most commonly used Food and Drug Administration-approved systemic therapy is liposomal doxorubicin (Doxil; Janssen Pharmaceuticals Inc., Raritan, New Jersey, USA) [99, 100] . Other approved agents include daunorubicin citrate liposomal injection (previously DaunoXome but no longer available in the United States), and paclitaxel [101, 102] . Interferon-a has activity [103] , but is poorly tolerated and is rarely used. Other chemotherapeutic agents with some activity include vincristine, vinblastine, doxorubicin, and bleomycin, but these have relatively less activity and greater toxicity. They are rarely used in the United States [16] , but are still used in low-resource settings [85] .
A more detailed description of Kaposi sarcoma treatment is beyond the scope of this article, and the reader is referred to other reviews [16, 98] . However, a few key points are worth mentioning. Specific Kaposi sarcoma therapy should only be instituted if there is a pathological diagnosis. Other than obtaining a biopsy for diagnosis, the only role for surgery is to remove a lesion that is anatomically problematic (e.g. one blocking an airway). Also, although long-term partial or even complete remissions can be attained, Kaposi sarcoma is not considered a tumor that can be 'cured', and the goal of therapy is acceptable palliation. This may require longterm therapy, sometimes intermittently. A good strategy is to continue a specific therapy until a remission or response plateau is achieved, and then taper or stop. There is no evidence that Kaposi sarcoma develops resistance to any therapeutic agent, and previously effective agents can often be reused in case of regrowth. Given that KSHV is a herpesvirus, patients are sometimes given antiherpes drugs. However, although cidofovir and ganciclovir are active against KSHV in the lab, prospective studies have shown no clinical activity in patients with established Kaposi sarcoma [104, 105] substantial unmet need for novel anti-Kaposi sarcoma agents, especially those suitable for resource-poor regions. Rapamycin is effective in renal transplantation recipients with Kaposi sarcoma [106] , and a recent study showed that it had some activity in AIDS-associated Kaposi sarcoma but also substantial pharmacologic interactions with antiretroviral drugs with strong cytochrome P450, family 3, subfamily A4 inhibitory activity [107] . Other targeted agents demonstrating some activity in early phase trials include imatinib [tyrosine kinase inhibitor of breakpoint cluster region protein-Abelson murine leukemia (BCR-ABL) viral oncogene homolog], interleukin-12, COL-3 (matrix metalloproteinase inhibitor), bevacizumab (antivascular growth factor inhibitor), and thalidomide [108] [109] [110] [111] [112] [113] . More recently, pomalidomide was shown to be tolerable and led to a 73% response rate, with activity in both AIDS-associated Kaposi sarcoma and HIV-unassociated Kaposi sarcoma [112] . A larger study is now in the planning stage to assess toxicity and activity and feasibility of administration of pomalidomide in Sub-Saharan Africa. A second study is evaluating safety and efficacy of pomalidomide in combination with liposomal doxorubicin in patients with more advanced Kaposi sarcoma (NCT02659930).
Primary effusion lymphoma
PEL is a rare B-cell malignancy that usually presents as an effusion in the pleura, peritoneum, or pericardium in HIV-infected patients. It may also present as noncavitary solid disease in lymph nodes, skin, or organs [12, 114] . Diagnosis requires demonstration of KSHV in the tumor cells; in about 80% of cases, they are coinfected with Epstein-Barr virus. In most cells, only latent KSHV genes are expressed; however, a minority express vIL-6 or other lytic genes [53] . Pathological examination usually shows expression of CD45, CD138, CD30, CD38, and human leukocyte antigen-antigen D related with lack of B-cell markers such as CD20, CD19, and immunoglobulins [115] . Abnormal phenotypes including tumors with T-cell markers have been described [116] . PEL tumor cells have clonal immunoglobulin gene rearrangements. There is provocative recent evidence that PEL may arise from KSHV-infected mesothelial cells which differentiate into 'B1-like' tumor cells [117] .
Although originally described in patients with advanced AIDS, recent data shows PEL may occur at higher CD4 þ T-cell counts, with a median of 204 cells/ml noted in one recent cohort [118] . Patients often present with fevers, malaise, and other inflammatory symptoms. In addition, they often present with a syndrome of hypoalbuminemia, thrombocytopenia, anemia, elevated IL-6, and elevated KSHV viral load that is relatively unique among HIVassociated lymphomas [119] . Clinicians should be vigilant for PEL in any HIV-infected patient with an effusion, especially if they have inflammatory symptoms or other KSHV-associated diseases. Historically, median survival was less than 6 months [120] . Nonetheless, PEL should be approached with curative intent. Combination therapy with a cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-based regimen and cART is commonly used as first line therapy, and may lead to long-term remissions in approximately 40% of patients [118] . Our group reported similar overall survival in 19 HIV-infected PEL patients treated with a modified etoposide, doxorubicin, vincristine, cyclophosphamide (DA-EPOCH)-based regimen and cART [121] . Interestingly, elevations in inflammatory cytokines, ferritin, and serum immunoglobulin E, but not usual parameters of lymphoma prognosis, were predictive of a poor outcome [121] . We are currently initiating a prospective trial of lenalidomide, which counters KSHV vFLIP upregulation of interferon regulatory factor 4, an important survival pathway in PEL [50, 122, 123] and KSHV-induced MHC-1 downregulation [124] , in combination with etoposide, doxorubicin, vincristine, cyclophosphamide (EPOCH), and rituximab (NCT02911142).
Multicentric Castleman disease
The term Castleman disease is used to describe a number of related lymphoproliferative disorders that vary based on anatomic distribution (unicentric vs. multicentric) and pathology [125] . KSHV is the cause of a distinct subset of MCD, KSHV-MCD, that usually develops in HIVinfected patients [14, 126] . It is clinically characterized by inflammatory symptoms, including fevers, night sweats, weight loss, cachexia, edema, and effusions [125, 127] . KSHV-MCD patients characteristically have lymphadenopathy and splenomegaly, and commonly also have respiratory, dermatologic, respiratory, and neurologic symptoms. Laboratory abnormalities include anemia, thrombocytopenia, hyponatremia, decreased albumin, elevated C-reactive protein, and elevated KSHV viral load as measured in both plasma and circulating mononuclear cells [59, [125] [126] [127] [128] . The course is characterized by intermittent flares and is usually fatal if not treated [129] . Patients with untreated KSHV-MCD are at high risk of developing large B-cell lymphoma [130] [131] [132] . The clinical presentation of KSHV-MCD is similar in HIV-uninfected patients [133] .
Pathophysiology and evaluation
Diagnosis of KSHV-MCD requires biopsy of an affected lymph node and demonstration of KSHV-infected plasmablasts (identified by LANA staining), usually in lymph nodes or spleen. KSHV-MCD lymph nodes have regressed germinal centers with vascularized core (sometimes a 'lollypop' sign) and mantle zone expansion with KSHV-infected plasmablastic cells [132] . A substantial proportion of these plasmablasts express vIL-6, and a subset of these show lytic activation [53, 134] . Interestingly, although plasmablasts are polyclonal, they are monotypic and express immunoglobulin M and l [132] . Inflammatory symptoms result from production of a variety of cytokines and factors, especially interleukin-6, interleukin-10, and vIL-6 [57, 59, 135] . Nearly all patients have elevated interleukin-6 levels during flares, whereas a substantial subset have elevated vIL-6 [42, 59] . vIL-6 plays a critical role and helps induce interleukin-6 production [58] . Direct activation of KSHV vIL-6 by X-box-binding protein type 1 in infected plasmablasts can upregulate vIL-6 without the need for full lytic induction of KSHV [134] . There is evidence that KSHV v-FLIP plays an important additional role in KSHV-MCD pathogenesis [136] . There is also evidence that certain KSHV miRNAs sequences may be associated with an increased risk of KSHV-MCD [60] . Interestingly, a cytokine excess syndrome similar to KSHV-MCD and associated with increased interleukin-6 has been observed in cancer patients treated with chimeric antigen receptor T cells [137] . 18 F-fluorodeoxyglucose PET scans of patients with KSHV-MCD often show hypermetabolic symmetrical lymphadenopathy and splenomegaly and PET may be useful in selecting lymph nodes for biopsy and excluding concurrent lymphoma. The diagnosis of KSHV-MCD is often missed, and physicians should be vigilant for this condition in patients with Kaposi sarcoma and symptoms or characteristic laboratory abnormalities. C-reactive protein is elevated during flares and can be used as a rough screening test along with evaluation of KSHV viral load. Patients with KSHV-MCD can deteriorate quickly because of sepsis-like syndromes, which are often mistakenly believed to be bacterial in origin.
KSHV-MCD is considered a rare disorder. However, it is almost certainly underreported. Improved diagnostic coding of Castleman disease may improve future epidemiologic studies. Unlike Kaposi sarcoma, KSHV-MCD often arises in patients with relatively preserved CD4 þ T-cell counts, and there is evidence that its incidence may be increasing with the introduction of cART [138] . Interestingly, KSHV-MCD may be associated with defects in invariant natural killer T-cells [139] . There are few cases reported in sub-Saharan Africa, despite the very high prevalence of KSHV and HIV coinfection. We have seen several African immigrants with KSHV-MCD in our studies in the National Institutes of Health (NIH) Clinical Center [59, 140, 141] , suggesting that many cases are missed in Africa. This may be changing, and a recent case series of KSHV-MCD was reported from Malawi [142] . Given our improved understanding of KSHV-MCD, it is quite possible that some patients with fevers and inflammatory symptoms in the AIDS epidemic had KSHV-MCD.
Treatment of Kaposi sarcoma-associated herpesvirus-multicentric Castleman disease
Without treatment, KSHV-MCD is generally lethal. Before specific therapies were developed, observed overall survival was two years or less [125, 127] . However, there have been substantial advances, and long-term remissions and survival can be attained in most cases [16, 143] . Rituximab (monoclonal antibody targeting CD20 antigen), alone or in combination with other agents, has dramatically improved outcomes, as demonstrated in three prospective studies and several cohort studies [133, 141, [144] [145] [146] [147] [148] . Rituximab as a single agent [145, 146] leads to resolution of MCD symptoms in excess of 90%. The high rate of success along with a well tolerated toxicity profile led to the recommendation of rituximab as a first-line treatment option. Relapse-free survival after rituximabbased therapy is 70-80%, and maintenance therapy does not appear to be required [147] . However, rituximab may have limitations in patients with low CD4 þ T-cell counts, severe symptoms, organ dysfunction, and patients with coexisting Kaposi sarcoma, as rituximab can lead to worsening of Kaposi sarcoma [145, 146, 149, 150] . Patients with KSHV-MCD flares can be extremely sick with a sepsis-like appearance and require treatment in an intensive care unit, where they may quickly respond when appropriately treated. The addition of cytotoxic chemotherapy to rituximab has been recommended for patients with advanced KSHV-MCD manifested by a poor performance status (Eastern Cooperative Oncology Group performance status 2), organ dysfunction, hemophagocytcic syndrome or severe hemolytic anemia, and either concurrent liposomal doxorubicin or etoposide has been used in this setting. Our group has studied the combination of rituximab and liposomal doxorubicin in patients with KSHV-MCD and Kaposi sarcoma or with severe KSHV-MCD [141] ; the rationale was that in the latter group, the liposomal doxorubicin may provide additional killing of the KSHV-MCD plasmablasts. We observed major clinical and biochemical responses in 94 and 88% of patients respectively and on overall 3-year survival of 81% [141] . Also, although one patient developed Kaposi sarcoma, five of six patients with concomitant Kaposi sarcoma had improvement.
Another prospectively studied approach is virus-activated cytotoxic therapy using high-dose zidovudine (ZDV) and valganciclovir (a prodrug of ganciclovir). This is based on in-vitro observations that the KSHV lytic genes ORF21 and ORF36 can phosphorylate ganciclovir, leading to a toxic moiety and that ORF21 can similarly phosphorylate ZDV [151] [152] [153] . A substantial subset of KSHV-MCD plasmablasts express lytic genes, and based on this, our group evaluated high-dose ZDV and valganciclovir in MCD patients. The combination yielded major clinical responses in 86% of patients, with major biochemical responses in 50% [140] . There are some limitations to this approach, including inadequate activity in patients with advanced disease, dose-limiting cytotoxicity requiring intermittent dosing, and high pill burden. However, combined with maintenance therapy or treatment of relapses, the overall survival was 86% at 12 months or beyond [140] .
In addition to the KSHV-MCD-specific treatments listed above, HIV-infected patients should receive cART. Glucocorticosteroids can be useful during flares [16] ; however, patients should be weaned as soon as possible because of their inadequacy in controlling KSHV-MCD in the long term and their potential to worsen Kaposi sarcoma. Because of the role of interleukin-6 in KSHV-MCD, there has been an interest in exploring the use of monoclonal antibodies targeting interleukin-6 signaling, such as tocilizumab or siltuximab in KSHV-MCD. However, given the importance of other cytokines [59] , such as vIL-6, it is not evident that they would be sufficient, and their use is discouraged outside the setting of a clinical trial. We are, currently, evaluating tocilizumab alone or in combination with virus activated cytotoxic therapy (NCT01441063).
Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome
Several years ago, our group observed that occasional patients with KSHV infection had a symptom profile that resembled KSHV-MCD but did not have KSHV-MCD. In a retrospective analysis, we identified six such patients [42] . In none were we able to make a pathologic diagnosis of KSHV-MCD or identify another condition to account for the findings. Four had Kaposi sarcoma, but the other two did not have any tumors. There are several mechanisms by which KSHV can increase cytokine production, and we hypothesized that the symptoms in these patients resulted from direct or indirect cytokine activation by KSHV. Further study showed that these patients had elevated vIL-6, human interleukin-6, interleukin-10, and other cytokines and factors, as well as a high KSHV viral load [42] . We have proposed the term KICS to describe these patients and developed a prospective case definition (Table 4) [17, 154] . We subsequently initiated a prospective study, and recently reported the first 10 patients [17] . Interestingly, all 10 patients had Kaposi sarcoma, and two also had PEL; this may reflect our referral pattern, as the patients were all initially referred for other KSHV malignancies. PET scans showed increased uptake by the tumors, but not the generalized lymph node uptake seen in KSHV-MCD [17] . Kaposi sarcoma did not respond to standard therapy in many of these patients, and overall they fared poorly; in total, nine of our 16 patients with KICS died, often from progressive KSHV-related tumors. Since our original publication, other investigators have reported similar cases [155] . Many questions remain, such as the source of the cytokine production. It is also unclear how to best treat this condition. We have been treating the underlying tumors, and in addition, exploring approaches developed for KSHV-MCD: high-dose ZDV and valganciclovir, or liposomal doxorubicin and pomalidomide.
The nomenclature is not standardized. There are several clinical differences between KICS patients and those with KSHV-MCD, and we restrict the term KSHV-MCD to those patients with the appropriate pathologic findings, and consider other patients with interleukin-6-related inflammatory symptoms and elevated KSHV viral load to have KICS, even if they have a concurrent malignancy. In patients with PEL and KICS, one could argue that KICS is a severe manifestation of 'B symptoms', however, given the common viral cause with KSHV-MCD, severity of symptoms, and cytokine profile that can also be observed in certain patients with Kaposi sarcoma or even without KSHV malignancy, we find the term KICS useful for considering these patients as a group. This is an area of active investigation that may lead to an improved understanding of disease pathogenesis in these high-risk patients, and modified classification of KSHV-MCD and KICS may be warranted in the future.
Conclusion
The discovery of KSHV and its identification as the cause of Kaposi sarcoma [9, 10] opened the door to a number of lines of inquiry and new insights. It is now appreciated that KSHV can cause several diseases, several of which had not been previously recognized. We have come a long way to understanding the biology of KSHV and disease pathogenesis, and are starting to develop therapeutic approaches targeting specific pathways. Even so, there is much more work to be done. Transmission rates of KSHV Kaposi sarcoma-associated herpesvirus diseases Gonçalves et al. 1911 continue to be high in certain populations, and we do not have a vaccine or even a clear understanding of the modes of transmission. Efforts to better understand how KSHV is spread and the ways that this can be reduced through education and public health strategies are needed. There are also many unanswered questions regarding KSHV biology and the ways in which this virus induces disease. Although therapy has improved for Kaposi sarcoma and KSHV-MCD, the prognosis for PEL and high-risk Kaposi sarcoma remains poor, and there remains a need for improved and less toxic therapies. Finally, it should be stressed that recognized and unrecognized KSHV-related diseases continue to be a major public health problem in sub-Saharan Africa, and there is an urgent need for improved prevention, diagnosis, and therapy that can be utilized in resource-poor areas.
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